These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20605207)

  • 1. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
    Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
    Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
    Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
    Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
    Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
    Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
    Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
    Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
    Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
    Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
    J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
    Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
    J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
    Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
    Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
    Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
    Burchert A; Saussele S; Eigendorff E; Müller MC; Sohlbach K; Inselmann S; Schütz C; Metzelder SK; Ziermann J; Kostrewa P; Hoffmann J; Hehlmann R; Neubauer A; Hochhaus A
    Leukemia; 2015 Jun; 29(6):1331-5. PubMed ID: 25712735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
    Cortes J; Giles F; O'Brien S; Thomas D; Garcia-Manero G; Rios MB; Faderl S; Verstovsek S; Ferrajoli A; Freireich EJ; Talpaz M; Kantarjian H
    Blood; 2003 Jul; 102(1):83-6. PubMed ID: 12637317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.